| Literature DB >> 34880313 |
Brian S Finlin1, Hasiyet Memetimin1, Amy L Confides2, Beibei Zhu1, Philip M Westgate3, Esther E Dupont-Versteegden2, Philip A Kern4.
Abstract
Acute cold induces beige adipocyte protein marker expression in human subcutaneous white adipose tissue (SC WAT) from both the cold treated and contralateral leg, and the immune system regulates SC WAT beiging in mice. Cold treatment significantly increased the gene expression of the macrophage markers CD68 and 86 in SC WAT. Therefore, we comprehensively investigated the involvement of macrophages in SC WAT beiging in lean and obese humans by immunohistochemistry. Cold treatment significantly increased CD163/CD68 macrophages in SC WAT from the cold treated and contralateral legs of lean and obese subjects, and had similar effects on CD206/CD68 macrophages, whereas the effects on CD86/CD68 macrophages were inconsistent between lean and obese. However, linear regression analysis did not find significant relationships between the change in macrophage numbers and the change in UCP1 protein abundance. A high percentage of CD163 macrophages in SC WAT expressed UCP1, and these UCP1 expressing CD163 macrophages were significantly increased by cold treatment in SC WAT of lean subjects. In conclusion, our results suggest that CD163 macrophages are involved in some aspect of the tissue remodeling that occurs during SC WAT beiging in humans after cold treatment, but they are likely not direct mediators of the beiging process.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34880313 PMCID: PMC8655049 DOI: 10.1038/s41598-021-03014-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Genes significantly regulated in SC WAT of the cold treated leg of obese research participants.
| Genea | Function | Pre counts | Pre SEM | Post counts | Post SEM | Fold change | P-value |
|---|---|---|---|---|---|---|---|
| FNDC5 | Secreted factor (promotes beiging) | 20 | 2 | 16 | 1 | 0.783 | 0.009 |
| IL18 | Cytokine | 85 | 8 | 109 | 13 | 1.288 | 0.015 |
| ADIPOR1 | Adiponectin Receptor | 2847 | 168 | 2232 | 163 | 0.784 | 0.020 |
| CD68 | Macrophage marker (pan) | 1309 | 227 | 1646 | 302 | 1.257 | 0.024 |
| TIMP2 | Extracellular matrix remodeling | 3475 | 251 | 3093 | 194 | 0.890 | 0.028 |
| CCL18 | Chemokine | 703 | 238 | 1536 | 482 | 2.185 | 0.035 |
| ANGPTL1 | Angiogenesis regulator | 345 | 23 | 282 | 38 | 0.818 | 0.036 |
| F3 | Secreted factor | 709 | 58 | 551 | 61 | 0.777 | 0.042 |
| EBF3 | Brown fat marker | 608 | 29 | 509 | 46 | 0.837 | 0.043 |
| CD86 | Macrophage marker (M1) | 107 | 9 | 139 | 19 | 1.296 | 0.048 |
| FGF2 | Secreted factor | 1289 | 113 | 1088 | 143 | 0.844 | 0.050 |
| CD163 | Macrophage Marker (M2) | 1240 | 109 | 1639 | 239 | 1.322 | 0.06 |
aGene expression was measured with a custom codeset[22] using the Nanostring nCounter system. The expression level of the gene (nCounter counts) and the SEM are indicated. The fold-change in gene expression (post / pre) is also indicated. Data were analyzed by a paired, two-tailed Student’s t-test.
Genes significantly regulated in SC WAT of the contralateral leg of obese research participants.
| Genea | Function | Pre counts | Pre SEM | Post counts | Post SEM | Fold change | P-value |
|---|---|---|---|---|---|---|---|
| EBF3 | Brown fat marker | 608 | 29 | 505 | 30 | 0.830 | 0.003 |
| TEK | Angiogenesis | 437 | 31 | 335 | 21 | 0.767 | 0.003 |
| FOXO1 | Transcription regulation | 1037 | 40 | 858 | 41 | 0.827 | 0.006 |
| ACACA | Fatty Acid metabolism | 166 | 15 | 144 | 15 | 0.870 | 0.007 |
| F3 | Secreted factor | 709 | 58 | 534 | 54 | 0.754 | 0.009 |
| FGF2 | Secreted factor | 1289 | 113 | 1019 | 75 | 0.791 | 0.012 |
| SIRT1 | Transcription regulation | 467 | 22 | 422 | 22 | 0.903 | 0.013 |
| BCL2 | Apoptosis | 617 | 14 | 489 | 44 | 0.792 | 0.021 |
| ANGPT4 | Angiogenesis | 14 | 2 | 11 | 1 | 0.784 | 0.023 |
| LEP | Adipokine | 4558 | 793 | 3900 | 594 | 0.856 | 0.023 |
| HMOX1 | Heme metabolism | 942 | 84 | 3066 | 781 | 3.255 | 0.036 |
| CCL18 | Chemokine | 703 | 238 | 1451 | 411 | 2.065 | 0.037 |
| CD86 | Macrophage marker (M1) | 107 | 9 | 137 | 16 | 1.287 | 0.041 |
| VEGFA | Angiogenesis | 810 | 50 | 925 | 58 | 1.142 | 0.045 |
| LOX | Extracellular matrix | 1514 | 87 | 1792 | 117 | 1.183 | 0.047 |
| CD68 | Macrophage marker (pan) | 1309 | 227 | 1712 | 306 | 1.308 | 0.048 |
| CD163 | Macrophage marker (M2) | 1240 | 109 | 1575 | 139 | 1.270 | 0.061 |
aGene expression was measured with a custom codeset[22] using the Nanostring nCounter system. The expression level of the gene (nCounter counts) and the SEM are indicated. The fold-change in gene expression (post / pre) is also indicated. Data were analyzed by a paired, two-tailed Student’s t-test.
Figure 1Representative images of macrophage immunohistochemistry. Human SC WAT was co-stained with antibodies against CD163 and CD68 (A), CD206 and CD68 (B), or CD86 and CD68 (C) before and after cold treatment as indicated. Fluorescence in each individual channel is presented followed by a merged image. Arrows indicate cells that co-stain with each specific macrophage antibody, CD68 (red), and that are DAPI positive (blue). Scale bars: 10 m.
Figure 2Quantification of inflammatory and anti-inflammatory macrophages in SC WAT of research participants in response to acute cold treatment. (A) to (C) Quantification of CD86/68, CD206/68, and CD163/68 positive macrophages in lean (n = 15–17) and obese (n = 8) research participants at baseline and in SC WAT from the cold and contralateral legs after 10 days of acute cold exposure. Data represent means ± SEM and were analyzed by RM MANOVA as described in research design and methods. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (lean n = 17; obese n = 8).
Figure 3Analysis of the change in inflammatory and anti-inflammatory macrophages in SC WAT of obese research participants in response to mirabegron and acute cold treatment. The change (post–pre) in macrophages in SC WAT was calculated for obese subjects treated with cold or for subjects treated with mirabegron using previous published data[3]. (A) to (C) Analysis of the change in CD86/68, CD206/68, and CD163/68 positive macrophages in response to mirabegron (n = 13) or cold (n = 8). Data represent means ± SEM and were analyzed by ANOVA as described in research design and methods. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (lean n = 17; obese n = 8).
Figure 4Representative images of UCP1 and CD163 co-staining. (A) Human SC WAT was co-stained with UCP1 and CD163 antibodies before and after cold treatment as indicated. Fluorescence in each individual channel is presented followed by a merged image. Arrows indicate cells that co-stain with UCP1 (red) and CD163 (green), and that are DAPI positive (blue). (B) and (C) No primary antibody controls for the co-staining are presented. Scale bars: 10 m.
Figure 5Quantification of UCP1 positive macrophages in SC WAT of research participants in response to acute cold treatment. (A) and (B) Quantification of CD163/UCP1 and CD206/UCP1positive macrophages in lean (n = 17) and obese (n = 8) research participants at baseline and in SC WAT from the cold and contralateral legs after 10 days of acute cold exposure. Data represent means ± SEM and were analyzed by RM MANOVA as described in research design and methods. *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.1 (lean n = 17; obese n = 8).
Figure 6Quantification of the percentage of CD163 macrophages that express UCP1 in response to acute cold treatment. The percentage of CD163 macrophages that express UCP1 before and after cold is indicated. Data represent means ± SEM.
Linear regression analysis of the change in macrophages and change in UCP1.
| Macrophage type | Leg | r2 | P-valuea |
|---|---|---|---|
| CD206/CD68 | Cold | 0.026 | 0.56 |
| CD206/CD68 | Contralateral | 0.330 | 0.02b |
| CD163/CD68 | Cold | 0.106 | 0.20 |
| CD163/CD68 | Contralateral | 0.002 | 0.87 |
| CD86/CD68 | Cold | < 0.0001 | 0.99 |
| CD86/CD68 | Contralateral | 0.076 | 0.28 |
| CD206/CD68 | Cold | 0.033 | 0.67 |
| CD206/CD68 | Contralateral | 0.117 | 0.41 |
| CD163/CD68 | Cold | 0.204 | 0.26 |
| CD163/CD68 | Contralateral | 0.002 | 0.91 |
| CD86/CD68 | Cold | 0.066 | 0.54 |
| CD86/CD68 | Contralateral | 0.028 | 0.69 |
aLinear regression analysis was performed on the change in macrophages (post–pre) versus the change in UCP1. The change in UCP1 was calculated from previously published data[4]. bP < 0.05.
Linear regression analysis of the change in CD163/CD68 macrophages and change gene expression.
| Genea | Leg | r2 | P-valueb |
|---|---|---|---|
| Adiponectin | Cold | 0.006 | 0.81 |
| Adiponectin | Contralateral | 0.004 | 0.85 |
| PPAR | Cold | 0.10 | 0.31 |
| PPAR | Contralateral | 0.006 | 0.81 |
| PPAR | Cold | 0.13 | 0.26 |
| PPAR | Contralateral | 0.05 | 0.50 |
| Fatty Acid Synthase | Cold | 0.05 | 0.50 |
| Fatty Acid Synthase | Contralateral | 0.07 | 0.42 |
| Leptin | Cold | 0.17 | 0.18 |
| Leptin | Contralateral | 0.21 | 0.13 |
| FABP4 | Cold | 0.24 | 0.10 |
| FABP4 | Contralateral | 0.03 | 0.60 |
| PGC1 | Cold | 0.04 | 0.53 |
| PGC1 | Contralateral | 0.05 | 0.50 |
| Adiponectin | Cold | 0.03 | 0.69 |
| Adiponectin | Contralateral | 0.13 | 0.38 |
| PPAR | Cold | 0.10 | 0.44 |
| PPAR | Contralateral | 0.30 | 0.16 |
| PPAR | Cold | 0.01 | 0.78 |
| PPAR | Contralateral | 0.05 | 0.59 |
| Fatty Acid Synthase | Cold | 0.003 | 0.90 |
| Fatty Acid Synthase | Contralateral | 0.07 | 0.51 |
| Leptin | Cold | 0.01 | 0.82 |
| Leptin | Contralateral | 0.01 | 0.78 |
| FABP4 | Cold | 0.22 | 0.24 |
| FABP4 | Contralateral | 0.29 | 0.17 |
| PGC1 | Cold | 0.23 | 0.23 |
| PGC1 | Contralateral | 0.15 | 0.34 |
aLinear regression analysis was performed on the change in CD163/CD68 macrophages (post–pre) versus the change in the expression of the indicated gene.